RNA PROCESSING MECHANISMS CONTROLLING HIV LATENCY
Grant number: 1129320 | Funding period: 2017 - 2019
Successful HIV remission and cure, where patients can live normally without daily drug therapy and risk of transmitting infectious virus, will critically depend on understanding the mechanisms that control the expression of viral messenger RNA and proteins. This project further explores the mechanisms controling poorly understood steps in the proecssing of viral mRNA that are required for HIV protein produciton, and identifies new targets and strategies to drive HIV into permanent remission.
Related publications (9)
The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency
Georges Khoury, Michelle Y Lee, Sri H Ramarathinam, James McMahon, Anthony W Purcell, Secondo Sonza, Sharon R Lewin, Damian FJ Purcell
HIV-1 Tat protein is essential for virus production. RNA-binding proteins that facilitate Tat production may be absent or downregu..
Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents
William Nguyen, Jonathan Jacobson, Kate E Jarman, Timothy R Blackmore, Helene Jousset Sabroux, Sharon R Lewin, Damian F Purcell, Brad E Sleebs
A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently ..
Functional properties and sequence variation of HTLV-1 p13
Maria Omsland, Micol Silic-Benussi, Ramona Moles, Sarkis Sarkis, Damian FJ Purcell, David Yurick, Georges Khoury, Donna M D'Agostino, Vincenzo Ciminale, Genoveffa Franchini
Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that driv..
Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection
Georges Khoury, Charlene Mackenzie, Lilia Ayadi, Sharon R Lewin, Christiane Branlant, Damian FJ Purcell
Tat protein is essential to fully activate HIV transcription and processing of viral mRNA, and therefore determines virus expressi..
p30 protein: a critical regulator of HTLV-1 viral latency and host immunity
Ramona Moles, Sarkis Sarkis, Veronica Galli, Maria Omsland, Damian FJ Purcell, David Yurick, Georges Khoury, Cynthia A Pise-Masison, Genoveffa Franchini
The extraordinarily high prevalence of HTLV-1 subtype C (HTLV-1C) in some isolated indigenous communities in Oceania and the sever..
Role of HTLV-1 orf-I encoded proteins in viral transmission and persistence
Sarkis Sarkis, Veronica Galli, Ramona Moles, David Yurick, Georges Khoury, Damian FJ Purcell, Genoveffa Franchini, Cynthia A Pise-Masison
The human T cell leukemia virus type 1 (HTVL-1), first reported in 1980 by Robert Gallo's group, is the etiologic agent of both ca..
Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models
William Nguyen, Jonathan Jacobson, Kate E Jarman, Helene Jousset Sabroux, Leigh Harty, James McMahon, Sharon R Lewin, Damian F Purcell, Brad E Sleebs
The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates l..
Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics
Sri H Ramarathinam, Stephanie Gras, Sheilajen Alcantara, Amanda WS Yeung, Nicole A Mifsud, Secondo Sonza, Patricia T Illing, Elias N Glaros, Robert J Center, Shane R Thomas, Stephen J Kent, Nicola Ternette, Damian FJ Purcell, Jamie Rossjohn, Anthony W Purcell
The recognition of pathogen‐derived peptides by T lymphocytes is the cornerstone of adaptive immunity, whereby intracellular antig..
HIV latency reversing agents act through Tat post translational modifications
Georges Khoury, Talia M Mota, Shuang Li, Carolin Tumpach, Michelle Y Lee, Jonathan Jacobson, Leigh Harty, Jenny L Anderson, Sharon R Lewin, Damian FJ Purcell
BACKGROUND: Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV ..